BioCentury
ARTICLE | Tools & Techniques

Yale takes CRISPR beyond editing, turning cold tumors hot

Yale team aims CRISPR at tumor cells in an editing-free vaccine that boosts neoantigen production

October 15, 2019 12:16 AM UTC
Updated on Oct 16, 2019 at 6:24 PM UTC

A Yale team has developed a new use for CRISPR as a cancer vaccine that turns cold tumors hot by boosting neoantigen expression, rather than editing genes.

In the realm of cancer, CRISPR’s application to drug development has primarily been in target discovery and ex vivo engineering of T cell therapies such as CAR Ts. Both commonly rely on the technology making cuts to the genome...

BCIQ Company Profiles

Yale University